Physician profile
Brian M Sullivan
NPI 1891767547
$8,339.68
in general payments reported to CMS, 2019-2025
34 companies · $1,424 in 2025
The $1,424 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $844 · 2021: $1,046 · 2022: $1,499 · 2023: $1,362 · 2024: $1,024 · 2025: $1,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,760 · Education: $49.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,759.95 |
| Education | $49.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,816.55 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,013.27 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $806.38 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $797.66 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $552.68 | 2019-2025 | |
| Ardelyx, INC. | $402.75 | 2022-2025 | Ibsrela |
| Pfizer INC. | $325.65 | 2019-2025 | |
| Celgene Corporation | $280.23 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $164.83 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $151.18 | 2019-2024 | |
| Celltrion USA INC. | $125.42 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $102.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $83.61 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $82.25 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $77.72 | 2025 | Omvoh |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $67.54 | 2019-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $59.52 | 2022-2023 | Dupixent |
| Qol Medical, LLC | $54.76 | 2025 | Sucraid |
| Shire North American Group INC | $40.58 | 2019 | |
| Amgen INC. | $38.77 | 2020-2022 | |
| Genzyme Corporation | $29.65 | 2022 | |
| Biocon Biologics INC | $29.54 | 2023 | Hulio |
| Redhill Biopharma INC. | $27.66 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $26.65 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $24.02 | 2020 | |
| Shield Therapeutics INC | $21.65 | 2025 | |
| Novo Nordisk INC | $21.52 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $21.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.86 | 2024 | Zeposia |
| Fresenius Kabi USA, LLC | $17.99 | 2024 | Idacio |
| W. L. Gore & Associates, INC. | $17.52 | 2023 | Gore Cardioform Septal Occluder |
| Intra-Sana Laboratories | $16.11 | 2022 | |
| Providence Medical Technology, INC. | $13.57 | 2019 | |
| Ambu INC. | $8.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.